Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)	8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)	Incidence of nonrelapse mortality	1503	1632	Four-year cumulative incidences of nonrelapse mortality were 24% and 13% in Flu-TBI and TLI-ATG patients, respectively (P = 0.5).
Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)	8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)	Incidence of relapse/progression at four years	1372	1502	Four-year cumulative incidences of relapse/progression were 22% and 50% in Flu-TBI and TLI-ATG patients, respectively (P = 0.017).
Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)	8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)	Incidence of grade II-IV acute GVHD at 180 days	777	935	The 180-day cumulative incidences of grade II-IV acute GVHD (primary endpoint) were 12.2% versus 8.9% in Flu-TBI and TLI-ATG patients, respectively (P = 0.5).
Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)	8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)	4-year overall survival and progression-free survival	1642	1825	4-year overall (OS) and progression-free survivals (PFS) were 53% and 54%, respectively, in the Flu-TBI arm, versus 54% (P = 0.9) and 37% (P = 0.12), respectively, in the TLI-ATG arm.
Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)	8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)	Incidence of moderate/severe chronic GVHD at 2 years	936	1081	Two-year cumulative incidences of moderate/severe chronic GVHD were 40.8% versus 17.8% in Flu-TBI and TLI-ATG patients, respectively (P = 0.017).
Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)	8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)	4-year overall survival and progression-free survival	1633	1825	Finally, 4-year overall (OS) and progression-free survivals (PFS) were 53% and 54%, respectively, in the Flu-TBI arm, versus 54% (P = 0.9) and 37% (P = 0.12), respectively, in the TLI-ATG arm.
Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)	8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)	Incidence of nonrelapse mortality	1503	1631	Four-year cumulative incidences of nonrelapse mortality were 24% and 13% in Flu-TBI and TLI-ATG patients, respectively (P = 0.5)
Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm)	8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm)	Incidence of grade II-IV acute GVHD at 180 days	-1	-1	The 180-day cumulative incidences of grade II-IV acute GVHD were 12.2% versus 8.9% in Flu-TBI and TLI-ATG patients, respectively (P = 0.508)
